WFDC2 and cancer: While serum remains a reliable and well-validated sample type for biomarkers such as WFDC2 (23, 24), plasma offers broader proteomic coverage and contributes to a more comprehensive understanding of the role of WFDC2 in cancer progression and its potential as a biomarker.